Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Apr;4(2):221-30.
doi: 10.1586/ehm.11.11.

Clinical management of aplastic anemia

Amy E Dezern  1 , Robert A Brodsky
Affiliations
Review

Clinical management of aplastic anemia

Amy E Dezern et al. Expert Rev Hematol. 2011 Apr.

Abstract

Acquired aplastic anemia is a potentially fatal bone marrow failure disorder that is characterized by pancytopenia and a hypocellular bone marrow. Hematopoietic stem-cell transplantation or bone marrow transplantation (BMT) is the treatment of choice for young patients who have a matched sibling donor. Immunosuppression with either anti-thymocyte globulin and cyclosporine or high-dose cyclophosphamide is an effective therapy for patients who are not suitable BMT candidates owing to age or lack of a suitable donor. Results of BMT from unrelated and mismatched donors are improving, but presently this treatment option is best reserved for those patients who do not respond, relapse or develop secondary clonal disorders following immunosuppressive therapy. Efforts are currently underway to both improve immunosuppressive regimens and to expand the application of BMT.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Results of high-dose cyclophosphamide therapy for severe aplastic anemia
(A) Overall survival after high-dose cyclophosphamide therapy for 44 treatment-naive patients (upper line) and 23 patients refractory to prior immunosuppressive therapy (lower line), p = 0.03 (log rank test). (B) Failure-free survival after high-dose cyclophosphamide therapy for 44 treatment-naive patients (upper line) and 23 patients refractory to prior immunosuppressive therapy (lower line), p = 0.07 (log rank test). This research was originally published in [76]. © The American Society of Hematology.
See this image and copyright information in PMC

References

    1. Ehrlich P. [On the case of anemia with remarks on regenerative bone marrow changes] Charite-Annalen. 1888;13:301–309.
    1. Nakanishi K, Taniguchi T, Ranganathan V, et al. Interaction of FANCD2 and NBS1 in the DNA damage response. Nat. Cell Biol. 2002;4(12):913–920. - PubMed
    1. Uechi T, Nakajima Y, Chakraborty A, Torihara H, Higa S, Kenmochi N. Deficiency of ribosomal protein S19 during early embryogenesis leads to reduction of erythrocytes in a zebrafish model of Diamond–Blackfan anemia. Hum. Mol. Genet. 2008;17(20):3204–3211. - PubMed
    1. Chakraborty A, Uechi T, Higa S, Torihara H, Kenmochi N. Loss of ribosomal protein L11 affects zebrafish embryonic development through a p53-dependent apoptotic response. PLoS One. 2009;4(1):e4152. - PMC - PubMed
    1. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509–2519. - PMC - PubMed

Publication types

MeSH terms

Substances